Tu Nguyen

Tu Nguyen

Auto-generated profile, based on publicly available information

Tu Nguyen

Department of Radiological Sciences, University of California, Los Angeles, CA 92521, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Cell Reports
Verified
Journal Article
Open access
TNTu Nguyen
Tu Nguyen
BKBrian James Kirsch
Brian James Kirsch
RARyoichi Asaka
Ryoichi Asaka
KNKarim Nabi
Karim Nabi
AQAddison Quinones
Addison Quinones
ALAnne Le
Anne Le
N-acetyl-aspartyl-glutamate (NAAG) is a peptide-based neurotransmitter that has been extensively studied in many neurological diseases. In this study, we show a specific role of NAAG in cancer. We found that NAAG is more abundant in higher grade cancers and is a source of glutamate in cancers expressing glutamate carboxypeptidase II (GCPII), the enzyme that hydrolyzes NAAG to glutamate and N-acetyl-aspartate (NAA). Knocking down GCPII expression through genetic alteration or pharmacological inhibition of GCPII results in a reduction of both glutamate concentrations and cancer growth. Moreover, targeting GCPII in combination with glutaminase inhibition accentuates these effects. These findings suggest that NAAG serves as an important reservoir to provide glutamate to cancer cells through GCPII when glutamate production from other sources is limited. Thus, GCPII is a viable target for cancer therapy, either alone or in combination with glutaminase inhibition.

24 June 2019 in Proteomics
Verified
Journal Article
Open access
PDF file
SUSunag Udupa
Sunag Udupa
SNStephanie Nguyen
Stephanie Nguyen
GHGiang Hoang
Giang Hoang
TNTu Nguyen
Tu Nguyen
AQAddison Quinones
Addison Quinones
ALAnne Le
Anne Le
The targeting of glutamine metabolism specifically via pharmacological inhibition of glutaminase 1 (GLS1) has been translated into clinical trials as a novel therapy for several cancers. The results, though encouraging, show room for improvement in terms of tumor reduction. In this study, the glutaminase II pathway is found to be upregulated for glutamate production upon GLS1 inhibition in pancreatic tumors. Moreover, genetic suppression of glutamine transaminase K (GTK), a key enzyme of the glutaminase II pathway, leads to the complete inhibition of pancreatic tumorigenesis in vivo unveiling GTK as a new metabolic target for cancer therapy. These results suggest that current trials using GLS1 inhibition as a therapeutic approach targeting glutamine metabolism in cancer should take into account the upregulation of other metabolic pathways that can lead to glutamate production; one such pathway is the glutaminase II pathway via GTK.

1 May 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
AWAlyssa Walker
Alyssa Walker
ASAnju Singh
Anju Singh
ETEllen Tully
Ellen Tully
JWJuhyung Woo
Juhyung Woo
ALAnne Le
Anne Le
EGEdward Gabrielson
Edward Gabrielson

18 January 2021 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
LMLina Ma
Lina Ma
LNLolita S Nidadavolu
Lolita S Nidadavolu
HYHuanle Yang
Huanle Yang
JLJackie Langdon
Jackie Langdon
RWReyhan Westbrook
Reyhan Westbrook
PAPeter M Abadir
Peter M Abadir
Chronic inflammation (CI) in older adults is associated with reduced health span and life span. Interleukin-6 (IL-6) is one CI marker that is strongly associated with adverse health outcomes and mortality in aging. We have previously characterized a mouse model of frailty and chronic inflammatory pathway activation (IL-10tm/tm, IL-10 KO) that demonstrates the upregulation of numerous proinflammatory cytokines, including IL-6. We sought to identify a more specific role for IL-6 within the context of CI and aging and developed a mouse with targeted deletion of both IL-10 and IL-6 (IL-10tm/tm/IL-6tm/tm, DKO). Phenotypic characteristics, cytokine measurements, cardiac myocardial oxygen consumption, physical function, and survival were measured in DKO mice and compared to age- and gender-matched IL-10 KO and wild-type mice. Our findings demonstrate that selective knockdown of IL-6 in a frail mouse with CI resulted in the reversal of some of the CI-associated changes. We observed increased protective mitochondrial-associated lipid metabolites, decreased cardiac oxaloacetic acid, improved myocardial oxidative metabolism, and better short-term functional performance in DKO mice. However, the DKO mice also demonstrated higher mortality. This work shows the pleiotropic effects of IL-6 on aging and frailty.

28 June 2023 in Genes
Verified
Journal Article
Open access
PDF file
KUKarim Ullah
Karim Ullah
YLYan Li
Yan Li
QLQiaoshan Lin
Qiaoshan Lin
KPKaichao Pan
Kaichao Pan
TNTu Nguyen
Tu Nguyen
RWRongxue Wu
Rongxue Wu
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, with septic cardiomyopathy being a common and severe complication. Despite its significant clinical impact, the molecular mechanisms underlying sepsis-induced cardiomyopathy (SICM) remain incompletely understood. In this study, we performed a comparative analysis of whole transcriptome profiles using RNA sequencing in mouse hearts in two widely used mouse models of septic cardiomyopathy. CLP-induced sepsis was achieved by surgical cecal ligation and puncture, while LPS-induced sepsis was induced using a 5 mg/kg intraperitoneal (IP) injection of lipopolysaccharide (LPS). For consistency, we utilized sham-operated mice as the control for septic models. Our aim was to identify key genes and pathways involved in the development of septic cardiomyopathy and to evaluate the similarities and differences between the two models. Our findings demonstrated that both the CLP and lipopolysaccharide LPS methods could induce septic heart dysfunction within 24 h. We identified common transcriptional regulatory regions in the septic hearts of both models, such as Nfkb1, Sp1, and Jun. Moreover, differentially expressed genes (DEGs) in comparison to control were involved in shared pathways, including regulation of inflammatory response, regulation of reactive oxygen species metabolic process, and the JAK-STAT signaling pathway. However, each model presented distinctive whole transcriptome expression profiles and potentially diverse pathways contributing to sepsis-induced heart failure. This extensive comparison enhances our understanding of the molecular basis of septic cardiomyopathy, providing invaluable insights. Accordingly, our study also contributes to the pursuit of effective and personalized treatment strategies for SICM, highlighting the importance of considering the specific causative factors.

21 May 2025 in Hepatology
Verified
Journal Article
Open access
TNTu Nguyen
Tu Nguyen
YSYonghwan Shin
Yonghwan Shin
ARAravinth Ruppa
Aravinth Ruppa
AKAbigail S. Krall
Abigail S. Krall
JPJanet Pham
Janet Pham
JCJason Chiang
Jason Chiang
Background and Aims: Thermal ablation is the standard-of-care treatment modality with curative intent for early-stage nonresectable HCC, but a durable response is limited, with up to 40% of patients with HCC eventually experiencing local recurrence on posttreatment surveillance. While thermal ablation has been established to cause immediate cell death in the center of the thermal ablation zone, its metabolic impact in the peri-ablational region remains unclear. We aimed to elucidate the metabolic mechanism by which Galectin-1 (Gal-1) promotes thermal-ablation–induced hyperthermia resistance in HCC and demonstrate the therapeutic potential of inhibiting Gal-1 in combination with thermal ablation in vivo . Approach and Results: Proteomic analysis was performed using an untargeted approach on pre-ablation formalin-fixed paraffin-embedded biopsy specimens of thermal ablation responders (n=32) and nonresponders (n=23). Gal-1 was found to be overexpressed in thermal ablation nonresponders compared with responders. Moreover, HCC with Gal-1 overexpression demonstrated reduced sensitivity to hyperthermia in vitro and increased utilization of glycolysis and the downstream tricarboxylic acid (TCA) cycle under hyperthermia-induced stress. Gal-1–overexpressing HCC enhanced its metabolic utilization through Gal-1–facilitated GM1-ganglioside breakdown, producing galactose to increase the metabolic influxes into glycolysis and consequently the downstream TCA cycle. In-vivo studies showed that inhibiting Gal-1 in combination with thermal ablation significantly reduced tumor size compared with either monotherapy thermal ablation or Gal-1 inhibition alone. Conclusions: Gal-1 can mediate hyperthermia resistance in HCC and can potentially be modulated as a therapeutic target to reduce rapid progression after thermal ablation.